304 related articles for article (PubMed ID: 11020800)
1. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors.
Hernandez-Alcoceba R; Pihalja M; Wicha MS; Clarke MF
Hum Gene Ther; 2000 Sep; 11(14):2009-24. PubMed ID: 11020800
[TBL] [Abstract][Full Text] [Related]
2. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by alpha-lactalbumin promoter.
Li X; Zhang J; Gao H; Vieth E; Bae KH; Zhang YP; Lee SJ; Raikwar S; Gardner TA; Hutchins GD; VanderPutten D; Kao C; Jeng MH
Mol Cancer Ther; 2005 Dec; 4(12):1850-9. PubMed ID: 16373700
[TBL] [Abstract][Full Text] [Related]
5. Improved glioblastoma treatment with Ad5/35 fiber chimeric conditionally replicating adenoviruses.
Hoffmann D; Meyer B; Wildner O
J Gene Med; 2007 Sep; 9(9):764-78. PubMed ID: 17640083
[TBL] [Abstract][Full Text] [Related]
6. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
7. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
8. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy.
Doronin K; Kuppuswamy M; Toth K; Tollefson AE; Krajcsi P; Krougliak V; Wold WS
J Virol; 2001 Apr; 75(7):3314-24. PubMed ID: 11238857
[TBL] [Abstract][Full Text] [Related]
9. Gene therapy for prostate cancer by controlling adenovirus E1a and E4 gene expression with PSES enhancer.
Li X; Zhang YP; Kim HS; Bae KH; Stantz KM; Lee SJ; Jung C; Jiménez JA; Gardner TA; Jeng MH; Kao C
Cancer Res; 2005 Mar; 65(5):1941-51. PubMed ID: 15753394
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
11. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
12. Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice.
Sarkar D; Su ZZ; Vozhilla N; Park ES; Gupta P; Fisher PB
Proc Natl Acad Sci U S A; 2005 Sep; 102(39):14034-9. PubMed ID: 16172403
[TBL] [Abstract][Full Text] [Related]
13. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
14. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli.
Hoffmann D; Wildner O
BMC Biotechnol; 2006 Aug; 6():36. PubMed ID: 16887042
[TBL] [Abstract][Full Text] [Related]
15. Cancer-specific targeting of a conditionally replicative adenovirus using mRNA translational control.
Stoff-Khalili MA; Rivera AA; Nedeljkovic-Kurepa A; DeBenedetti A; Li XL; Odaka Y; Podduturi J; Sibley DA; Siegal GP; Stoff A; Young S; Zhu ZB; Curiel DT; Mathis JM
Breast Cancer Res Treat; 2008 Mar; 108(1):43-55. PubMed ID: 17508279
[TBL] [Abstract][Full Text] [Related]
16. Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo.
Sipo I; Wang X; Hurtado Picó A; Suckau L; Weger S; Poller W; Fechner H
Gene Ther; 2006 Jan; 13(2):173-86. PubMed ID: 16136163
[TBL] [Abstract][Full Text] [Related]
17. Effects of the Ad5 upstream E1 region and gene products on heterologous promoters.
Hoffmann D; Jogler C; Wildner O
J Gene Med; 2005 Oct; 7(10):1356-66. PubMed ID: 15945123
[TBL] [Abstract][Full Text] [Related]
18. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity.
Sauthoff H; Pipiya T; Heitner S; Chen S; Bleck B; Reibman J; Chang W; Norman RG; Rom WN; Hay JG
Mol Ther; 2004 Oct; 10(4):749-57. PubMed ID: 15451459
[TBL] [Abstract][Full Text] [Related]
19. Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma.
Liu Y; Ye T; Sun D; Maynard J; Deisseroth A
Hum Gene Ther; 2004 Jul; 15(7):637-47. PubMed ID: 15242524
[TBL] [Abstract][Full Text] [Related]
20. Combining high selectivity of replication via CXCR4 promoter with fiber chimerism for effective adenoviral oncolysis in breast cancer.
Stoff-Khalili MA; Rivera AA; Stoff A; Michael Mathis J; Rocconi RP; Matthews QL; Numnum MT; Herrmann I; Dall P; Eckhoff DE; Douglas JT; Siegal GP; Zhu ZB; Curiel DT
Int J Cancer; 2007 Feb; 120(4):935-41. PubMed ID: 17131341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
